Passion for Innovation. Compassion for Patients.™
Daiichi Sankyo Europe GmbH
Dear User,
This website provides you with information only for healthcare professionals. According to the drug
promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have
full access to our website. To visit our page please login.
European News
Daiichi Sankyo announces new data to be presented at the ISPOR EU Congress 2016 analysing the safety, efficacy and cost-effectiveness of LIXIANA®▼ (edoxaban)
Daiichi Sankyo
2016-10-13 08:30:01
Daiichi Sankyo announces new data to be presented at the ISPOR EU Congress 2016 analysing the safety, efficacy
Daiichi Sankyo Announces First Patient Enrolled in Phase 3 QuANTUM-First Trial Investigating Quizartinib in Newly-Diagnosed FLT3-ITD+ Acute Myeloid Leukemia
Daiichi Sankyo
2016-12-08 15:15:01
Daiichi Sankyo Announces First Patient Enrolled in Phase 3 QuANTUM-First Trial Investigating Quizartinib in
New analysis shows maintained efficacy and safety of LIXIANA®▼ (edoxaban) in patients with acute VTE requiring a reduced dose based on clinical criteria
Daiichi Sankyo
2016-09-30 11:22:16
New analysis shows maintained efficacy and safety of LIXIANA®▼ (edoxaban) in patients with acute VTE requiring
Daiichi Sankyo to Present at ESMO 2016 Late-Breaking Clinical Data for Novel HER2-Targeting Antibody Drug Conjugate
Daiichi Sankyo
2016-09-28 15:36:29
Daiichi Sankyo to Present at ESMO 2016 Late-Breaking Clinical Data for Novel HER2-Targeting Antibody Drug
Expert recommendations from the Future of Anticoagulation Report are to be undertaken to improve Atrial Fibrillation management
Daiichi Sankyo
2016-09-29 15:45:01
Expert recommendations from the Future of Anticoagulation Report are to be undertaken to improve Atrial
Daiichi Sankyo Provides Update on Her3-Lung Study of Patritumab in Non-Small Cell Lung Cancer (NSCLC)
Daiichi Sankyo
2016-07-11 17:45:01
Daiichi Sankyo Provides Update on Her3-Lung Study of Patritumab in Non-Small Cell Lung Cancer (NSCLC)
Daiichi Sankyo Partners With World Thrombosis Day
Daiichi Sankyo
2016-03-16 12:19:33
Daiichi Sankyo Partners With World Thrombosis Day
UK’s NICE recommends once-daily LIXIANA® (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation
Daiichi Sankyo
2016-06-22 16:50:57
UK’s NICE recommends once-daily LIXIANA® (edoxaban) for preventing stroke and systemic embolism in patients
Target 70%: At ESC Congress 2015 Experts Discussed French, Italian and Austrian Initiatives for Better Blood Pressure Control
Daiichi Sankyo
2016-03-16 13:00:05
Target 70%: At ESC Congress 2015 Experts Discussed French, Italian and Austrian Initiatives for Better Blood
UK’s NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism in adults
Daiichi Sankyo
2016-06-22 16:52:22
UK’s NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent deep vein
More Stories
